Bag of Tr1Xs: Off-the-Shelf Type 1 Treg Shows Phase I Promise for GvHD
In a clinical first, Tr1X Bio showed immune reconstitution and engraftment for allogeneic Tr1 cell therapy, establishing clinical safety and efficacy
Tr1X Presents First Clinical Data Demonstrating Proof of Safety and Proof of Mechanism With Allogeneic Off-the-Shelf Tr1 Regulatory T Cell Therapy TRX103
First clinical data from Phase 1 dose-escalation study in patients undergoing HLA-mismatched hematopoietic stem cell transplantation (HSCT). TRX103 demonstrated exceptional safety, accelerated immune reconstitution, and dose-dependent persistence and induction of Tr1 and FOXP3+ regulatory T cells. All patients achieved successful engraftment and donor chimerism following transplantation.
A Phase I, First in Human Open Label Study to Evaluate the Safety and Tolerability of TRX103 Cell Infusion in Subjects with Hematological Malignancies Undergoing HLA-Mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)
Use of post-transplant Cyclophosphamide (PTCy) for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) has reduced the incidence of graft versus host disease (GvHD), and expanded donor options for patients to include haploidentical and mismatched unrelated donors. Though PTCy is effective at reducing acute GvHD, 30-40% of patients receiving peripheral blood stem cell (PBSC) grafts […]